GSK to evaluate Vectura delivery technology

GlaxoSmithKline (LSE:GSK; GSK) will evaluate Vectura's Aerocine and related dry powder formulation technologies for inhaled delivery of therapeutics to treat inflammatory and other constrictive airway diseases. Vectura (Bath, U.K.) will receive option and development fees during the evaluation period, and is eligible for license fees, milestones and royalties if GSK exercises its option to license Vectura's technology for the pharma company's respiratory pipeline. ...